Indian Pharma Companies Shift Focus Beyond US Amid Tariff Threat and Iran Conflict

Indian Pharma Companies are actively evaluating markets beyond the United States, exploring European, Asian and domestic options, assessing regulatory pathways and commercial viability; these steps aim to protect revenue streams and ensure drug availability.

Tariff Threat could raise export duties on pharmaceutical products, increasing costs for Indian exporters and prompting a reassessment of pricing strategies, supply‑chain configurations, and negotiations with trade officials for possible exemptions.

Iran Conflict is tightening the flow of raw materials used in drug manufacturing, creating supply constraints for Indian firms that rely on imports from the region; the shortage risk extends to essential medicines such as antibiotics and insulin.

Industry Response includes diversifying sourcing, considering alternative suppliers, accelerating domestic production of key ingredients, and investing in local API manufacturing capacity to mitigate the combined impact of tariffs and geopolitical disruptions.